RECRUITINGINTERVENTIONAL
Effects of Intravenous Metabolic Recovery Agent in Elderly Septic Patients on Prognosis and Microcirculation.
Clinical Study of the Effect of Intravenous Hydrocortisone Combined With Vitamin C and Vitamin B1 Infusion on Prognosis and Sublingual Microcirculation in Elderly Patients With Sepsis or Septic Shock.
About This Trial
This study intends to observe the effect of intravenous hydrocortisone combined with vitamin C and vitamin B1 infusion on the prognosis and sublingual microcirculation in patients with sepsis or septic shock through a prospective randomized controlled study method.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age ≥60 and ≤85 years old;
- Diagnosis of sepsis or septic shock;
- Clinical judgment for hydrocortisone treatment;
- Signing willing to sign a consent form.
Who Should NOT Join This Trial:
- patients in palliative care;
- uncontrolled malignancy with multiple metastases;
- ineffective surgical intervention for the infectious agent;
- estimated death within 24 hours;
- glucocorticoids used in the last 7 days;
- allergy to hydrocortisone, vitamin c or vitamin B1;
- inability to measure sublingual microcirculation.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age ≥60 and ≤85 years old;
* Diagnosis of sepsis or septic shock;
* Clinical judgment for hydrocortisone treatment;
* Signing Informed Consent.
Exclusion Criteria:
* patients in palliative care;
* uncontrolled malignancy with multiple metastases;
* ineffective surgical intervention for the infectious agent;
* estimated death within 24 hours;
* glucocorticoids used in the last 7 days;
* allergy to hydrocortisone, vitamin c or vitamin B1;
* inability to measure sublingual microcirculation.
Treatments Being Tested
DRUG
Metabolic resuscitation agent
Intervention group will receive intravenous hydrocortisone (200mg every 24 hours), vitamin C (1.5g every 6 hours), and thiamine (200 mg every 12 hours).
DRUG
Hydrocortisone
Placebo group will receive intravenous hydrocortisone 200mg every 24 hours.
Locations (1)
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China